Clinicians should talk to men ages 55 to 69 about the potential benefits and harms of screening, according to the U.S. Preventive Services Task Force. For men ages 70 years and older, the potential benefits of prostate-specific antigen (PSA)-based screening do not outweigh the harms, the Task Force said.
Researchers used administrative health claims from Jan. 1, 2012, to June 30, 2015, among a cohort of privately insured adults ages 18 to 64 years who had surgery between 2013 and 2014.
This week's quiz asks readers to determine the most appropriate additional treatment for a 28-year-old man with recurrent nephrolithiasis.
Researchers conducted a retrospective cohort study and self-controlled case series to determine the frequency of prescriptions for less than 30 days of oral corticosteroids and any association with adverse events.
The first webinar in the series will discuss “Leading Practice Transformation and Quality Improvement in Times of Change.”
2017 marks the 50th anniversary of ACP's Medical Knowledge Self-Assessment Program® (MKSAP®), ACP's trusted educational resource.